Osang Healthcare to Supply HbA1c Analyzers to Mexican Government on a Large Scale

Osang Healthcare, a company specializing in in vitro diagnostics, announced on May 13 that it will supply its glycated hemoglobin (HbA1c) analyzer, the "HemoCue® HbA1c 501 System," to Mexico's large-scale public healthcare procurement market through HemoCue AB. HemoCue AB is a subsidiary of Danaher and a leading company in point-of-care diagnostic solutions.

HemoCue recently received the final award notification for the glycated hemoglobin analyzer from the main public healthcare products procurement agency under the Mexican Ministry of Health. Through HemoCue, Osang Healthcare will supply both the devices and cartridges of this product to the Mexican government over the next two years, with the final purchase order (PO) process currently underway. The company expects the order to be placed within approximately three months and is preparing for supply accordingly.

This contract was awarded as a result of a comprehensive evaluation of the product's technological capabilities and cost-effectiveness. Key competitive advantages included a broad measurement range, high accuracy, convenience of cartridge storage at room temperature, and a strict quality management system. The product will be supplied to medical sites throughout Mexico, and as major national medical institutions such as IMSS Bienestar participate, Osang Healthcare anticipates increased brand recognition across Central and South America.

A representative from Osang Healthcare stated, "This project is a testament to our technological expertise and global supply capabilities," adding, "We aim to maintain our competitive edge in upcoming follow-up bids through stable supply."

Meanwhile, HemoCue leads the point-of-care diagnostic solutions sector under the mission of "raising the quality of care, one test at a time, everywhere." The company supports healthcare professionals around the world in improving patient outcomes and work efficiency. Over the past 40 years, HemoCue has continuously innovated the possibilities of point-of-care diagnostics, offering a wide range of solutions for hemoglobin, glucose, glycated hemoglobin (HbA1c), as well as total leukocyte counts and differential testing. Danaher is a life sciences and diagnostics company dedicated to scientific and technological innovation for the advancement of human health, with HemoCue as one of its subsidiaries.

This content was produced with the assistance of AI translation services.